Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 8963 results
Found 8963 results.

Time Factors

Grant PM, Komarow L, Andersen J, et al. "Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection." PLoS ONE. 2010;5(7):e11416.
Coban H, Robertson K, Smurzynski M, et al. "Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen." AIDS. 2017;31(11):1565-1571.
Wagner GJ, Goggin K, Remien RH, et al. "A closer look at depression and its relationship to HIV antiretroviral adherence." Ann Behav Med. 2011;42(3):352-60.
J McCutchan A, Wu JW, Robertson K, et al. "HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients." AIDS. 2007;21(9):1109-17.
Campbell TB, Smeaton LM, Kumarasamy N, et al. "Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings." PLoS Med.. 2012;9(8):e1001290.
Luetkemeyer AF, Kendall MA, Nyirenda M, et al. "Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs." J. Acquir. Immune Defic. Syndr.. 2014;65(4):423-8.
Abraham AG, Lau B, Deeks S, et al. "Missing data on the estimation of the prevalence of accumulated human immunodeficiency virus drug resistance in patients treated with antiretroviral drugs in north america." Am. J. Epidemiol.. 2011;174(6):727-35.
Geng EH, Kahn JS, Chang OC, et al. "The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation." Clin. Infect. Dis.. 2011;53(10):1008-14.
Lok JJ, Bosch RJ, Benson CA, et al. "Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection." AIDS. 2010;24(12):1867-76.
Keil K, Hochreitter J, DiFrancesco R, et al. "Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application." Ther Drug Monit. 2007;29(1):103-9.
Tebas P, Zhang J, Yarasheski K, et al. "Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)." J. Acquir. Immune Defic. Syndr.. 2007;45(2):193-200.
Johnson BA, Ribaudo H, Gulick RM, Eron JJ. "Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times." Biometrics. 2013;69(3):732-40.
Tsibris AMN, Korber B, Arnaout R, et al. "Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo." PLoS ONE. 2009;4(5):e5683.
Mitsuyasu R, Gelman R, Cherng DWeng, et al. "The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328." Arch. Intern. Med.. 2007;167(6):597-605.
Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. "The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin." Aliment. Pharmacol. Ther.. 2011;33(11):1234-44.
Zolopa A, Andersen J, Powderly W, et al. "Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial." PLoS ONE. 2009;4(5):e5575.
Gerber JG, Kitch DW, Fichtenbaum CJ, et al. "Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186." J. Acquir. Immune Defic. Syndr.. 2008;47(4):459-66.
Vardhanabhuti S, Acosta EP, Ribaudo HJ, et al. "Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission." J. Infect. Dis.. 2013;208(4):662-71.
Benson CA, Vaida F, Havlir DV, et al. "A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086." J. Infect. Dis.. 2006;194(9):1309-18.
Krishnan S, Schouten JT, Jacobson DL, et al. "Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis." Oncology. 2011;80(1-2):42-9.
Kuritzkes DR, Ribaudo HJ, Squires KE, et al. "Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s." J. Infect. Dis.. 2007;195(8):1169-76.
Tsibris AMN, Sagar M, Gulick RM, et al. "In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject." J. Virol.. 2008;82(16):8210-4.
McMahon DK, Zheng L, Hitti J, et al. "Greater suppression of nevirapine resistance with 21- vs 7-day antiretroviral regimens after intrapartum single-dose nevirapine for prevention of mother-to-child transmission of HIV." Clin. Infect. Dis.. 2013;56(7):1044-51.
Yin MT, Kendall MA, Wu X, et al. "Fractures after antiretroviral initiation." AIDS. 2012;26(17):2175-84.
Venuto CS, Mollan K, Ma Q, et al. "Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202." J. Antimicrob. Chemother.. 2014;69(12):3300-10.
Sax PE, Tierney C, Collier AC, et al. "Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy." N. Engl. J. Med.. 2009;361(23):2230-40.
Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM. "Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s)." HIV Clin Trials. 2009;10(6):343-55.
Messer K, Vaida F, Hogan C. "Robust analysis of biomarker data with informative missingness using a two-stage hypothesis test in an HIV treatment interruption trial: AIEDRP AIN503/ACTG A5217." Contemp Clin Trials. 2006;27(6):506-17.
Cohn SE, Park J-G, Watts DH, et al. "Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions." Clin. Pharmacol. Ther.. 2007;81(2):222-7.
Stone ND, Dunaway SB, Flexner C, et al. "Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects." Antimicrob. Agents Chemother.. 2007;51(7):2351-8.

Pages